ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)
Year: 2016
Type: conference-abstract
Source: Neuro-Oncology
Authors: Martin van den Bent, Hui Gan, Andrew Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis Nabors, Kyriakos Papadopoulos, Marta Penas-Prado, John Simes, Tobias Walbert, Andrew Scott, Erica Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle Bain, Kyle Holen, David Maag, David Reardon
Institutions: Erasmus MC Cancer Institute, Columbia University Irving Medical Center, Northwestern University, Endeavor Health, University of California, San Francisco, Royal Brisbane and Women's Hospital, Henry Ford Hospital, University of Alabama at Birmingham, South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, National Health and Medical Research Council, Henry Ford Health, Austin Health, Olivia Newton-John Cancer Research Institute, AbbVie (United States), Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2563089000